Observational study on treatment patterns in advanced lung cancer with MET mutations
Real-World Treatment Patterns and Effectiveness of Targeted and Systemic Therapy in Patients With Advanced Lung Cancer Carrying MET Mutation-Positive
This study looks at how people with advanced lung cancer that has MET mutations are treated and how well those treatments work.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hunan Province Tumor Hospital Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT06183762 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect data on treatment patterns and effectiveness in patients with MET mutation-positive advanced lung cancer. It will gather information in an epidemiological manner, without altering current medical practices. Data will be collected both retrospectively from prior treatments and prospectively from patients undergoing treatment in the future. Eligible patients will be enrolled following NGS analysis of tumor tissue and informed consent.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with unresectable stage IIIB/IIIC or stage IV non-small cell lung cancer (NSCLC) confirmed by histology or cytology.
Not a fit: Patients with resectable lung cancer or those without MET mutations may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into effective treatment strategies for patients with MET mutation-positive advanced lung cancer.
How similar studies have performed: While this study follows a common observational approach, the specific focus on MET mutation-positive advanced lung cancer may provide novel insights, as similar studies have shown varying degrees of success in understanding treatment patterns.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients must be ≥18 years of age. 2. Provision of fully informed consent prior to any study specific procedures. 3. Histologically or cytologically confirmed, unresectable stage IIIB/IIIC or stage IV NSCLC. 4. Genetic variants of tumor tissue detected by NGS. Exclusion Criteria: None.
Where this trial is running
Changsha, Hunan
- Hunan Province Tumor Hospital — Changsha, Hunan, China (Recruiting)
Study contacts
- Study coordinator: Yongchang Zhang, MD
- Email: zhangyongchang@csu.edu.cn
- Phone: +8613873123436
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.